PLX: Protalix BioTherapeutics, Inc. Stock

by  •  • Comments Off on PLX: Protalix BioTherapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 83.28
Enterprise Value ($M) 79.90
Book Value ($M) 33.57
Book Value / Share 0.46
Price / Book 2.48
NCAV ($M) 19.07
NCAV / Share 0.26
Price / NCAV 4.37

Profitability (mra)
Return on Invested Capital (ROIC) 0.14
Return on Assets (ROA) 0.12
Return on Equity (ROE) 8.25

Liquidity (mrq)
Quick Ratio 1.12
Current Ratio 1.54

Balance Sheet (mrq) ($M)
Current Assets 69.93
Assets 84.43
Liabilities 50.87
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 65.49
Operating Income 10.46
Net Income 8.31
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -1.32
Cash from Investing -16.71
Cash from Financing 24.67

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-02 13G/A Nacht Marius 2.90 -21.58

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
2023-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-17 110,430 340,393 32.44
2024-04-16 78,794 268,605 29.33
2024-04-15 113,918 429,154 26.54
2024-04-12 95,168 59,050 161.17

(click for more detail)

Similar Companies
NNVC – NanoViricides, Inc. OGEN – Oragenics, Inc.
PHGE – BiomX Inc. PTN – Palatin Technologies, Inc.
SCPX – Scorpius Holdings, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Protalix BioTherapeutics